Kite Pharma, Inc. (NASDAQ:KITE) Declines -3.93% in Pre-market

Kite Pharma, Inc. (NASDAQ:KITE) Declines -3.93% in Pre-market

Kite Pharma, Inc. (NASDAQ:KITE) Declines -3.93% in Pre-market

Other equities analysts have also issued research reports about the company. Finally, Canaccord Genuity set a $75.00 target price on Kite Pharma and gave the stock a "buy" rating in a research report on Tuesday, November 29th.

02/22/2017 - Wells Fargo began new coverage on Kite Pharma, Inc. giving the company a "outperform" rating. Kite Pharma now has an average rating of "Buy" and an average target price of $71.34.

12/05/2016 - Kite Pharma, Inc. had its "buy" rating reiterated by analysts at Stifel Nicolaus. They now have a $74.00 price target on the stock. (NASDAQ:KITE) will be trading in the future. Company's distance from 20 day simple moving average is 46.41% and distance from 50-Day simple moving average is 56.52%.

"Data looks very good and above expectations, demonstrating a solid risk/benefit efficacy profile that should support rapid FDA approval, possibly by the end of this year" RBC Capital Markets analyst Michael Yee said in a note. Mr. Roy Doumani is one of the biggest insider owners in Kite Pharma, Inc.

Kite Pharma (NASDAQ:KITE) last announced its earnings results on Monday, February 27th. The company is expected to release $-1.72 EPS for current quarter according to 12 analysts whereas the company reported $-0.9 EPS during same quarter a year ago.

Yemen raid was success, gathered vital intelligence
They said US airstrikes targeted al-Qaeda artillery and other sites, and that no US Navy ships participated in the mission. The U.S. raid in January killed some two dozen civilians, including Abdullah Mabkhout al-Ameri.

Dow breaks 12-day record streak ahead of Trump speech
All the major indexes moved into record territory, with the DJIA up 303.31 points to 21,115.55 at the close of trading. The benchmark Kospi finished up 11.01 points or 0.53 percent at 2,102.65, the highest level since February 23.

Cleveland Browns: Franchise tag deadline on Terrelle Pryor passes
As expected, Browns WR Terrelle Pryor is not one of them, opening the door for the 27-year-old to possibly become a free agent. To play the PR game as a front office and coaching staff coming off of a 1-15 season is an uphill climb out of the gate.

The cloud company posted a loss of $36.9 million, or 28 cents per share, for its fiscal fourth quarter. Kite Pharma had a negative return on equity of 39.26% and a negative net margin of 994.89%. KITE has a beta of 0 and RSI is 77.67. During the same period in the previous year, the firm earned ($0.54) EPS.

Analysts are also projecting an Average Revenue Estimate for Kite Pharma, $5.6 Million in the Current Quarter. If you are viewing this news story on another publication, it was stolen and reposted in violation of US and global copyright and trademark law. The correct version of this story can be viewed at [[permalink]].

In related news, Chairman Arie Belldegrun sold 3,493 shares of the stock in a transaction on Tuesday, December 20th. The shares were sold at an average price of $50.56, for a total value of $505,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Its COO BUTITTA CYNTHIA M sold 38,882 company shares for 2856270, in a transaction on 2017-03-01. Following the completion of the sale, the chairman now directly owns 24,707 shares in the company, valued at approximately $1,256,598.02. The disclosure for this sale can be found here. BlackRock Fund Advisors now owns 1,751,216 shares of the biopharmaceutical company's stock valued at $97,823,000 after buying an additional 94,421 shares in the last quarter.

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Kite Pharma by 2.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 151,428 shares of the biopharmaceutical company's stock valued at $7,572,000 after buying an additional 14,802 shares during the last quarter. BB Biotech AG now owns 800,000 shares of the biopharmaceutical company's stock valued at $44,688,000 after buying an additional 50,000 shares in the last quarter. Bainco International Investors increased its stake in shares of Kite Pharma by 2,722.8% in the third quarter.

On Friday, January 6th, Jeffrey Wiezorek sold 1,500 shares of Kite Pharma stock. Moody Aldrich Partners LLC raised its position in Kite Pharma by 11.2% in the third quarter.

Related news